Harmonised Clinical Trial Budget Template for Fixed Cost Components

As part of SCRI’s ongoing efforts to strengthen Singapore’s clinical trials ecosystem and improve clinical trial start-up timelines, a harmonised clinical trial budget template for fixed cost components has been developed to support efficient budget preparations for Industry Sponsored Trial (IST) across Singapore’s public healthcare institutions (PHIs) with effect from 1 May 2026.

This initiative has engaged approximately 50 PHIs and industry partners across the ecosystem, with the shared goal of facilitating efficient and timely budget negotiations, and expediting clinical trial start-up processes in Singapore.

The harmonised template serves as a cost-neutral, overarching guideline that enhances clarity on charges for fixed cost components, thereby reducing the need for multiple rounds of clarification between sites and sponsors. It streamlines budget negotiations through the following key features:

• Standardised budget terminologies

• Harmonised budget structure for fixed cost components

• Improved clarity and transparency in site budgets

The template is applicable to all ISTs regardless of phase, nature or therapeutic areas. As the template only addresses fixed cost components, other charges (including pass-through costs and direct patient costs) will continue to be reflected in site-specific budgets.

Note: The inclusion of a line-item cost in the template does not imply mandatory charging. Only charges relevant to study-specific requirements and necessary for trial conduct will be reflected in site budgets.

For more information, please contact ncb@scri.cris.sg